Cover Image

Not for Sale



View/Hide Left Panel

bility of infection, they believe that the disease is almost always mild. Hence, the motivation to prevent varicella in this target population will be substantially less than in the immunodeficient population, even though lay individuals might believe the vaccine to be highly effective. The moderate cost, estimated at $25 per dose, may act as a modest barrier to extensive vaccine utilization.


Provider Acceptance Physician acceptance of this vaccine for all susceptible normal persons probably will be similar to that of the lay population. In addition, physicians may have lingering concerns about the latent state and the possibility that the vaccine virus might induce more frequent or more severe episodes of herpes zoster.

Cost of Illness

The scope and purpose of the calculations included below are described in Chapters 4 and 7. These calculations are based on certain simplifying procedures and assumptions that have been judged not to compromise their utility for the purposes of this comparison. The total costs should be taken only as an approximation of the direct cost of this disease.

Total Cost of Disease Burden and Vaccine Preventable Illness Specifically for Varicella

Category A n/a

 

 

Category B

 

 

# of cases=3,788,337

 

 

approx. 20% of cases receive 1 phys. visit at $30

= $

22,730,000

approx. 20% of cases receive medication at $5

= $

3,788,000

[OTC medication]

 

 

 

TOTAL (B)

= $

26,518,000

Category C—encephalitis, pneumonia, Reye’s syndrome and other hospitalization

 

 

# of cases=6,501

 

 

100% of cases typically receive 3 days of ICU at $600/day

= $

11,702,000

100% of cases typically receive additional 3 days normal hospitalization at $400/day

= $

7,801,000

100% of cases typically receive diagnostic testing and treatment (i.e., EEGs, cranial monitoring, CT scans) at rate equivalent to daily inclusive hospital rate

 

 

3 days at $600/day

= $

11,702,000

3 days at $400/day

= $

7,801,000



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement